EP
KROS icon

Essential Partners’s Keros Therapeutics KROS Stock Holding History

Essential Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.95K Buy
259
+53
+26% +$580 ﹤0.01% 1769
2026
Q2 		$2.2K Buy
206
+75
+57% +$835 ﹤0.01% 1933
2026
Q1 		$1.45K Sell
131
-52
-28% -$803 ﹤0.01% 2115
2025
Q4 		$3.73K Sell
183
-759
-81% -$13.3K ﹤0.01% 1546
2025
Q3 		$14.9K Buy
942
+811
+619% +$12K ﹤0.01% 1011
2025
Q2 		$1.75K Buy
+131
New +$1.77K ﹤0.01% 1350

Other funds holding KROS

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's KROS Position: Q3 2026 in Review

Essential Partners increased its Keros Therapeutics (KROS) stake by 26% in Q3 2026, buying an estimated $580 and bringing the position to 259 shares worth $2.95K. The position accounts for ﹤0.01% of the portfolio, ranked #1769.

Essential Partners first reported a position in KROS in Q2 2025 and has held it in 6 quarters since. The position peaked at $14.9K in Q3 2025. 6 funds tracked by Wall St. Rank hold KROS as of Q3 2026.

  • Essential Partners held 259 shares of Keros Therapeutics worth $2.95K as of Q3 2026.
  • Essential Partners bought 53 Keros Therapeutics shares in Q3 2026, an estimated $580.
  • Keros Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1769 holding.
  • Essential Partners first reported a position in Keros Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Keros Therapeutics position peaked at $14.9K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.